NorthWest Biotherapeutics Inc (NWBO)

[AVII77]

I always thought he’d been invested in that stock. So it’s interesting to see that was his perspective so close to its big move up. And that he was very wrong in his assessment of it. If he was invested, then despite his negative interpretation, he still did well. If he wasn’t, then, oh well.

As I see Ex pointed out, this was my assessment of the ASCEND trial results.

I was spot on.

The ASCEND trial was not run by Amarin (that was the REDUCE-IT Trial).

The ASCEND Trial used a low dose Omega-3 fish oil comprised of both EPA and DHA.

Had it been successful, it would have made the commercial prospects of Amarin's Vascepa poor (why buy a brand name prescription product if you could get the same results with a generic Lovaza or OTC OM-3).

Had it failed (it did), the headlines were "another study proves OM-3 treatment worthless" (ignoring the more subtle, but important, point that Amarin uses a high dose of EPA w/o DHA).

To keep this On-Topic, it is not too far from what you might have envisioned for NWBO from the CLDX or IMUC Trials: Had they been successful, it would validate the immunotherapy approach to treating GBM (and competitors arise). Had they failed (they did) one might argue that the DCVax trial would fail too (ignoring the fact that the DCVax trial targets a broader suite of antigens - so it would be incorrect to ascribe the results from those trials to the DCVax trial).

Hope that clarify's Mavericks incorrect characterization of my view. All too many posters here have a hard time with reading comprehension of complex issues (and some struggle even with the not so complex stuff).